ReviewCurrent hypertension reports2015
Clinical Significance of Endothelial Dysfunction in Essential Hypertension.
Review in Current hypertension reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Pooled it
- Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension.Bioscience reports · 2020Pooled it
- Trial
- Trial
- Association between life's essential 8 and diabetic kidney disease: a population-based study.Renal failure · 2025Article
- Hemoglobin is associated with hypertension-mediated cardiovascular damages in hypertensive patients with high-altitude polycythemia.Internal and emergency medicine · 2025Article
- Association between urinary cotinine level and hypertensive disorders of pregnancy in women with uterine myoma: findings from the Japan Environment and Children's Study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Immune and Metabolic Mechanisms of Endothelial Dysfunction.International journal of molecular sciences · 2024Review
- Downregulation of microRNA‑221‑3p promotes angiogenesis of lipoprotein(a)‑injured endothelial progenitor cells by targeting silent information regulator 1 to activate the RAF/MEK/ERK signaling pathway.Molecular medicine reports · 2024Article
- Angiotensin II Induces Vascular Endothelial Dysfunction by Promoting Lipid Peroxidation-Mediated Ferroptosis via CD36.Biomolecules · 2024Article
- Ebbs and tides of endothelial KAmerican journal of physiology. Heart and circulatory physiology · 2024Article
- Effect of early endothelial function improvement on subclinical target organ damage in hypertensives.Scientific reports · 2024Article
- Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention.Frontiers in immunology · 2024Review
- Circulating microvesicles across a population with various degree of cardiovascular burden are associated with systolic blood pressure.Journal of human hypertension · 2023Review
- Clinical Significance of Altered Vascular Morphology and Function in Normotension.Current hypertension reports · 2023Review
- Angiotensin-(1-9) prevents angiotensin II-induced endothelial apoptosis through CNPY2/PERK pathway.Apoptosis : an international journal on programmed cell death · 2023Article
- Microvascular and Endothelial Dysfunction in Prediabetes.Life (Basel, Switzerland) · 2023Review
- Editorial: Endotheliopathies: Current concepts and importance in clinical practice.Frontiers in medicine · 2023Article
- Effects of acute aerobic exercise on arterial stiffness in transgender men.Frontiers in physiology · 2023Article
- Blunted Microvascular Reactivity in Psoriasis Patients in the Absence of Cardiovascular Disease, as Assessed by Laser Speckle Contrast Imaging.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endothelium is recognized as a major determinant of vascular physiology and pathophysiology. Over the last few decades, a plethora of studies have implicated endothelial dysfunction in the progression of atherosclerosis and the subclinical target organ damage observed in essential hypertension. However, the clinical significance of diagnosing endothelial dysfunction in patients with essential hypertension remains under investigation. Although a number of vascular and non-vascular markers of endothelial dysfunction have been proposed, there is an ongoing quest for a marker in the clinical setting that is optimal, inexpensive, and reproducible. In addition, endothelial dysfunction emerges as a promising therapeutic target of agents that are readily available in clinical practice. In this context, a better understanding of its role in essential hypertension becomes of great importance. Here, we aim to investigate the clinical significance of endothelial dysfunction in essential hypertension by accumulating novel data on (a) early diagnosis using robust markers with prognostic value in cardiovascular risk prediction, (b) the association of endothelial dysfunction with subclinical vascular organ damage, and (c) potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.